Future research might also use iPS cells as models to examine drug therapies for the treatment of alcohol use disorders or symptoms associated with alcohol withdrawal. A promising potential use for iPS cell technologies is to identify new drugs and drug targets, as well as to screen drugs for off-target toxicities (Cundiff and Anderson, 2011). Three of the most widely prescribed medications to treat alcohol use disorders include disulfiram, which disrupts alcohol metabolism, naltrexone, which antagonizes opioid receptors, and acamprosate, which disrupts glutamate signaling. However, each of these drugs has adverse effects associated with their use, and treatment efficacy varies among individuals, and this variation may be associated with different genotypes (Miller, 2008, Johnson et al., 2011, Ray et al., 2009). Additional research is currently focusing on additional drugs for the treatment of alcohol use disorders, such as topiramate, which targets glutamate and GABAA receptors (Miller, 2008, Johnson, 2010). Our results show that functional glutamate and GABAA receptors are expressed in iPS-derived neural cultures. Because the use of iPS cell technologies allows us to obtain neural cultures from individuals with
